These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 23559359

  • 1. Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study.
    Hori M, Nagai R, Izumi T, Matsuzaki M.
    Heart Vessels; 2014 Mar; 29(2):238-47. PubMed ID: 23559359
    [Abstract] [Full Text] [Related]

  • 2. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial.
    Lainscak M, Podbregar M, Kovacic D, Rozman J, von Haehling S.
    Respir Med; 2011 Oct; 105 Suppl 1():S44-9. PubMed ID: 22015086
    [Abstract] [Full Text] [Related]

  • 3. Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial.
    Contini M, Apostolo A, Cattadori G, Paolillo S, Iorio A, Bertella E, Salvioni E, Alimento M, Farina S, Palermo P, Loguercio M, Mantegazza V, Karsten M, Sciomer S, Magrì D, Fiorentini C, Agostoni P.
    Int J Cardiol; 2013 Oct 03; 168(3):2134-40. PubMed ID: 23506636
    [Abstract] [Full Text] [Related]

  • 4. The comparative effects of long-term carvedilol versus bisoprolol therapy on QT dispersion in patients with chronic heart failure.
    Aygul N, Ozdemir K, Duzenli MA, Aygul MU.
    Cardiology; 2009 Oct 03; 112(3):168-73. PubMed ID: 18654081
    [Abstract] [Full Text] [Related]

  • 5. Tolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure -- a randomized comparison.
    Galatius S, Gustafsson F, Atar D, Hildebrandt PR.
    Cardiology; 2004 Oct 03; 102(3):160-5. PubMed ID: 15334027
    [Abstract] [Full Text] [Related]

  • 6. Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure.
    Armenian SH, Hudson MM, Chen MH, Colan SD, Lindenfeld L, Mills G, Siyahian A, Gelehrter S, Dang H, Hein W, Green DM, Robison LL, Wong FL, Douglas PS, Bhatia S.
    BMC Cardiovasc Disord; 2016 Oct 04; 16(1):187. PubMed ID: 27716152
    [Abstract] [Full Text] [Related]

  • 7. BETAWIN-AHF study: effect of beta-blocker withdrawal during acute decompensation in patients with chronic heart failure.
    Miró Ò, Müller C, Martín-Sánchez FJ, Bueno H, Mebazaa A, Herrero P, Jacob J, Gil V, Escoda R, Llorens P, ICA-SEMES Research Group.
    Clin Res Cardiol; 2016 Dec 04; 105(12):1021-1029. PubMed ID: 27379611
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, Elsik M, Krum H, Hayward CS.
    J Am Coll Cardiol; 2010 Apr 27; 55(17):1780-7. PubMed ID: 20413026
    [Abstract] [Full Text] [Related]

  • 10. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial.
    Düngen HD, Apostolovic S, Inkrot S, Tahirovic E, Töpper A, Mehrhof F, Prettin C, Putnikovic B, Neskovic AN, Krotin M, Sakac D, Lainscak M, Edelmann F, Wachter R, Rau T, Eschenhagen T, Doehner W, Anker SD, Waagstein F, Herrmann-Lingen C, Gelbrich G, Dietz R, CIBIS-ELD investigators and Project Multicentre Trials in the Competence Network Heart Failure.
    Eur J Heart Fail; 2011 Jun 27; 13(6):670-80. PubMed ID: 21429992
    [Abstract] [Full Text] [Related]

  • 11. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.
    Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, Matsuzaki M, Takeshita A, Origasa H, Matsui K, Hosoda S, MUCHA Investigators.
    Am Heart J; 2004 Feb 27; 147(2):324-30. PubMed ID: 14760332
    [Abstract] [Full Text] [Related]

  • 12. Clinical status and outcome of Japanese heart failure patients with reduced or preserved ejection fraction treated with carvedilol.
    Mori Y, Nishikawa Y, Kobayashi F, Hiramatsu K.
    Int Heart J; 2013 Feb 27; 54(1):15-22. PubMed ID: 23428919
    [Abstract] [Full Text] [Related]

  • 13. Carvedilol: a review of its use in chronic heart failure.
    Keating GM, Jarvis B.
    Drugs; 2003 Feb 27; 63(16):1697-741. PubMed ID: 12904089
    [Abstract] [Full Text] [Related]

  • 14. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma.
    Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR.
    J Heart Lung Transplant; 2002 Dec 27; 21(12):1290-5. PubMed ID: 12490274
    [Abstract] [Full Text] [Related]

  • 15. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
    Komajda M, Lutiger B, Madeira H, Thygesen K, Bobbio M, Hildebrandt P, Jaarsma W, Riegger G, Rydén L, Scherhag A, Soler-Soler J, Remme WJ, CARMEN investigators and co-ordinators.
    Eur J Heart Fail; 2004 Jun 27; 6(4):467-75. PubMed ID: 15182773
    [Abstract] [Full Text] [Related]

  • 16. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
    Sun YP, Wei CP, Ma SC, Zhang YF, Qiao LY, Li DH, Shan RB.
    J Cardiovasc Pharmacol; 2015 May 27; 65(5):480-4. PubMed ID: 25945865
    [Abstract] [Full Text] [Related]

  • 17. Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension.
    Taniguchi T, Ohtani T, Mizote I, Kanzaki M, Ichibori Y, Minamiguchi H, Asano Y, Sakata Y, Komuro I.
    J Cardiol; 2013 Jun 27; 61(6):417-22. PubMed ID: 23548374
    [Abstract] [Full Text] [Related]

  • 18. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease.
    Kubota Y, Asai K, Furuse E, Nakamura S, Murai K, Tsukada YT, Shimizu W.
    Int J Chron Obstruct Pulmon Dis; 2015 Jun 27; 10():515-23. PubMed ID: 25784798
    [Abstract] [Full Text] [Related]

  • 19. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers.
    Lindenfeld J, Robertson AD, Lowes BD, Bristow MR, MOCHA (Multicenter Oral Carvedilol Heart failure Assessment) Investigators.
    J Am Coll Cardiol; 2001 Dec 27; 38(7):1950-6. PubMed ID: 11738299
    [Abstract] [Full Text] [Related]

  • 20. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
    Lancet; 1997 Feb 08; 349(9049):375-80. PubMed ID: 9033462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.